journal
MENU ▼
Read by QxMD icon Read
search

Hepatology International

journal
https://www.readbyqxmd.com/read/28210927/efficacy-and-safety-of-daclatasvir-plus-pegylated-interferon-alfa-2a-and-ribavirin-in-previously-untreated-hcv-subjects-coinfected-with-hiv-and-hcv-genotype-1-a-phase-iii-open-label-study
#1
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, Juan Berenguer, Natalia Zakharova, Hugo Cheinquer, Pierre Côté, Douglas Dieterich, Adrian Gadano, Gail Matthews, Jean-Michel Molina, Christophe Moreno, Juan Antonio Pineda, Federico Pulido, Antonio Rivero, Jurgen Rockstroh, Dennis Hernandez, Fiona McPhee, Timothy Eley, Zhaohui Liu, Patricia Mendez, Eric Hughes, Stephanie Noviello, Peter Ackerman
BACKGROUND: Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients. METHODS: AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks...
February 16, 2017: Hepatology International
https://www.readbyqxmd.com/read/28176203/lipid-profiles-of-donors-and-recipients-of-liver-transplant-like-father-like-son
#2
Kevin K W Chu, See Ching Chan, Sui Ling Sin, Albert C Y Chan, Kenneth S H Chok, Ignatius K P Cheng, Chung Mau Lo
BACKGROUND/PURPOSE: Dyslipidemia is common in liver transplant recipients. This retrospective study investigates whether donors play a role. METHODS: Prospectively collected data of donors and recipients of deceased-donor liver transplantation (DDLT) and living-donor liver transplantation (LDLT) were reviewed. Total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein (HDL) and fasting glucose were compared between groups. HDL ≥1.6 mmol/L at 2 years after transplant was considered the marker of a favorable post-transplant lipid profile in recipients...
February 7, 2017: Hepatology International
https://www.readbyqxmd.com/read/28155069/abstracts-of-the-26th-annual-conference-of-apasl-february-15-19-2017-shanghai-china
#3
(no author information available yet)
No abstract text is available yet for this article.
February 2, 2017: Hepatology International
https://www.readbyqxmd.com/read/28144812/clinical-validity-of-metroticket-calculator-in-transplant-patients-undergoing-prior-chemoembolization-for-hepatocellular-carcinoma
#4
Hyung-Don Kim, Gi-Won Song, Ju Hyun Shim, Seungbong Han, Jihyun An, Deok-Bog Moon, Kang Mo Kim, Young-Suk Lim, Gi-Young Ko, Shin Hwang, Han Chu Lee, Eunsil Yu, Kyu-Bo Sung, Sung-Gyu Lee
AIM: To test the predictive performance of the Metroticket calculator for survival after liver transplantation (LT) of patients with hepatocellular carcinoma (HCC) undergoing prior transarterial chemoembolization (TACE). METHODS: A total of 142 patients treated with TACE and subsequent LT who had arterial enhancing HCC(s) were entered into this analysis. Tumor parameters measured by the enhancement radiological method pre-LT or by pathology post-LT were incorporated into the Metroticket analysis...
January 31, 2017: Hepatology International
https://www.readbyqxmd.com/read/28124314/microalbuminuria-systemic-inflammation-and-multiorgan-dysfunction-in-decompensated-cirrhosis-evidence-for-a-nonfunctional-mechanism-of-hepatorenal-syndrome
#5
EDITORIAL
Vicente Arroyo
No abstract text is available yet for this article.
January 25, 2017: Hepatology International
https://www.readbyqxmd.com/read/28097531/living-donor-liver-transplant-ldlt-is-the-way-forward-in-asia
#6
Mohamed Rela, Mettu Srinivas Reddy
Living donor liver transplantation (LDLT) is currently the commonest form of liver transplantation in Asia. Efforts to improve the number of deceased donor liver transplantation have not been uniformly successful. We believe that THE unique combination of demographic, social, economic and political factors that exist in Asia will ensure that LDLT will continue to remain the predominant form of liver transplantation. While efforts to increase deceased donation rates should continue and intensify, progress in LDLT should also be supported and encouraged, as it will be the main workhorse of liver transplantation in Asia in the near and medium-term future...
January 17, 2017: Hepatology International
https://www.readbyqxmd.com/read/28097530/virus-induced-hepatocellular-carcinoma-with-special-emphasis-on-hbv
#7
REVIEW
Ming Wang, Dong Xi, Qin Ning
Hepatocellular carcinoma (HCC) is a common malignant tumor with high lethality, and the hepatitis B virus (HBV) is a chief cause. HBV can accelerate HCC via multiple mechanisms. First, HBV induces immune reactions that lead to repeated hepatic inflammation, fibrosis and a deficient immune microenvironment. Subsequently, HBV can modify host genes near the insertion point through DNA integration to cause host cell genome instability and to generate carcinogenic fusion proteins. Additionally, HBV expresses diverse active proteins, especially HBx and HBs, which have a range of transactivation functions such as regulation of apoptosis, interference with intracellular signaling pathways, and alteration of epigenetics...
January 17, 2017: Hepatology International
https://www.readbyqxmd.com/read/28083718/ledipasvir-sofosbuvir-without-ribavirin-is-effective-in-the-treatment-of-recurrent-hepatitis-c-virus-infection-post-liver-transplant
#8
Mohamed Shoreibah, Jordan Orr, DeAnn Jones, Jie Zhang, Krishna Venkata, Omar Massoud
BACKGROUND/AIM: Recurrent hepatitis C virus infection is a challenging complication post-liver transplant. Current guidelines recommend the combination of ribavirin and ledipasvir/sofosbuvir for 12 weeks for the treatment of recurrent HCV genotype 1 post-liver transplant. Data are limited on the use of ledipasvir/sofosbuvir without ribavirin. The aim of this study was to evaluate the use of ledipasvir/sofosbuvir without ribavirin for the treatment of recurrent hepatitis C virus post-liver transplant...
January 12, 2017: Hepatology International
https://www.readbyqxmd.com/read/28058576/hepatitis-b-reactivation-in-patients-receiving-immunosuppressive-therapy-a-hidden-menace
#9
EDITORIAL
Chih-Lin Lin, Jia-Horng Kao
No abstract text is available yet for this article.
January 5, 2017: Hepatology International
https://www.readbyqxmd.com/read/28040878/erratum-to-elbasvir-grazoprevir-for-treatment-of-chronic-hepatitis-c-virus-infection
#10
Chandana Papudesu, Shyamasundaran Kottilil, Shashwatee Bagchi
No abstract text is available yet for this article.
December 31, 2016: Hepatology International
https://www.readbyqxmd.com/read/27990610/existence-of-cancer-stem-cells-in-hepatocellular-carcinoma-myth-or-reality
#11
Keigo Machida
The cancer stem cell (CSC) hypothesis has been disproved in many cancers. CSCs may exist in blood cancer, while many epithelial cancers may not have CSCs but tumor-initiating cells (TICs). Several independent studies have provided strong evidence for existence of CSCs in brain, skin, and colon cancers (Mani et al. in Cell 133:704-715, 2008, Joseph et al. in Cancer Cell 13:129-140, 2008, Reya et al. in Nature 414:105-111, 2001), while the CSC hypothesis remains controversial (Magee et al. in Cancer Cell 21:283-296, 2012)...
December 18, 2016: Hepatology International
https://www.readbyqxmd.com/read/27933591/charcoal-hemoperfusion-in-the-treatment-of-medically-refractory-pruritus-in-cholestatic-liver-disease
#12
Wonngarm Kittanamongkolchai, Ziad M El-Zoghby, J Eileen Hay, Russell H Wiesner, Patrick S Kamath, Nicholas F LaRusso, Kymberly D Watt, Carl H Cramer, Nelson Leung
BACKGROUND: Pruritus is a distressing symptom in a considerable proportion of cholestatic patients and a few of them do not respond to conventional treatment. Charcoal hemoperfusion (CH) is an extracorporeal technique that is effective in eliminating protein-bound substances which may have accumulated during cholestasis. Several case reports have shown significant reduction of bilirubin in mechanical jaundice and neonatal hemolytic jaundice. However, the published data of CH for the treatment of refractory pruritus in cholestatic patients are scarce...
December 8, 2016: Hepatology International
https://www.readbyqxmd.com/read/27928718/sofosbuvir-velpatasvir-a-pangenotypic-drug-to-simplify-hcv-therapy
#13
REVIEW
Rebecca Lee, Shyam Kottilil, Eleanor Wilson
Treatment for chronic hepatitis C virus (HCV) has evolved rapidly from an interferon based regimen of modest efficacy with significant adverse events to a well-tolerated, highly effective all-oral directly acting antiviral (DAA) therapy. Although significant improvement in sustained virologic responses (SVR) has been reported with new DAAs for genotypes 1 and 4, effective treatments for genotype 3 have been lacking, and a single pill that can yield high SVR rates against HCV genotypes 1-6 has not been available until now...
December 7, 2016: Hepatology International
https://www.readbyqxmd.com/read/27909950/hatt-a-phase-iv-single-arm-open-label-study-of-sorafenib-in-taiwanese-patients-with-advanced-hepatocellular-carcinoma
#14
Shi-Ming Lin, Sheng-Nan Lu, Ping-Tsung Chen, Long-Bin Jeng, Shinn-Cherng Chen, Chi-Tan Hu, Sien-Sing Yang, Marie-Aude Le Berre, Xuan Liu, David Y Mitchell, Klaas Prins, Joachim Grevel, Carol A E Peña, Gerold Meinhardt
BACKGROUND: Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). This phase IV study assessed sorafenib efficacy/safety in Taiwanese patients with advanced HCC and Child-Pugh A status. METHODS: All patients received 400 mg sorafenib BID. Safety, efficacy, sorafenib pharmacokinetics, and Child-Pugh progression were evaluated. A hand-foot skin reaction (HFSR) prevention substudy assessed HFSR incidence and grade/severity and time to HFSR in 29 and 34 patients randomized to corticosteroid and noncorticosteroid ointments, respectively, and in 88 nonrandomized patients...
December 1, 2016: Hepatology International
https://www.readbyqxmd.com/read/27714680/live-donor-liver-transplantation-for-alcoholic-hepatitis
#15
Ashwani K Singal, Patrick S Kamath
Liver transplantation is a definitive therapy for patients with end-stage liver disease and cirrhosis, with improvement in survival and quality of life. Patients are carefully screened and selected for this modality of treatment to achieve maximum survival benefit. For example, a patient with hepatocellular carcinoma is a candidate if he or she is within Milan criteria and has no significant comorbidity. Similarly, patients with alcoholic cirrhosis are transplant candidates if they are deemed to have been rehabilitated from abusive alcohol consumption and are at low risk for recidivism...
January 2017: Hepatology International
https://www.readbyqxmd.com/read/27696157/prolonged-fibroblast-growth-factor-19-response-in-patients-with-primary-sclerosing-cholangitis-after-an-oral-chenodeoxycholic-acid-challenge
#16
Serge J Zweers, Elisabeth M de Vries, Martin Lenicek, Dagmar Tolenaars, D Rudi de Waart, Kiran V K Koelfat, Albert K Groen, Steven W M Olde Damink, Ulrich Beuers, Cyriel Ponsioen, Peter L M Jansen, Frank G Schaap
BACKGROUND: Bile salts likely contribute to liver injury in patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Fibroblast growth factor 19 (FGF19) is a bile salt-induced enterokine with hepatoprotective potential as it suppresses de novo bile salt synthesis. Here, we evaluated the bile salt receptor FXR/FGF19 gut-liver axis in PSC and PBC patients. METHODS: Fasted patients with PSC (n = 12) and PBC (n = 10), and healthy controls (HC; n = 10) were orally challenged with the natural FXR agonist chenodeoxycholic acid (CDCA 15 mg/kg)...
January 2017: Hepatology International
https://www.readbyqxmd.com/read/27282879/interferon-free-treatment-for-hcv-infected-patients-with-decompensated-cirrhosis
#17
REVIEW
Tatsuo Kanda
Progress in interferon-free treatment against hepatitis C virus (HCV) has remained a challenge in patients with decompensated cirrhosis due to a paucity of information on efficacy and safety profiles. This review illustrates that interferon-free treatment could result in greater than 85 % sustained virological response (SVR) rates in patients with HCV genotype 1 and decompensated cirrhosis. The combination of pangenotypic HCV NS5A inhibitor velpatasvir and HCV NS5B inhibitor sofosbuvir has demonstrated high SVR rates in patients with HCV genotypes 1, 2, 3, 4 or 6 and decompensated cirrhosis...
January 2017: Hepatology International
https://www.readbyqxmd.com/read/27826704/serum-inducible-protein-ip-10-is-a-disease-progression-related-marker-for-non-alcoholic-fatty-liver-disease
#18
Nozomu Wada, Akinobu Takaki, Fusao Ikeda, Tetsuya Yasunaka, Masahiro Onji, Kazuhiro Nouso, Atsuko Nakatsuka, Jun Wada, Kazuko Koike, Koji Miyahara, Hidenori Shiraha, Kazuhide Yamamoto, Hiroyuki Okada
BACKGROUND: The molecular pathogenesis of non-alcoholic steatohepatitis (NASH) is not well defined. The objective of the present study was to identify disease progression-related cytokines and investigate the molecular pathogenesis of such changes in NASH. METHODS: A study population of 20 non-alcoholic fatty liver (NAFL) and 59 NASH patients diagnosed by liver biopsy and 15 healthy volunteers was recruited. The serum pro- and anti-inflammatory cytokines were measured by a multiple enzyme-linked immunosorbent assay...
November 8, 2016: Hepatology International
https://www.readbyqxmd.com/read/27658394/functionally-aberrant-dendritic-cell-subsets-and-expression-of-dc-sign-differentiate-acute-from-chronic-hbv-infection
#19
Sukriti Sukriti, Nirupma Trehanpati, Manoj Kumar, Chandana Pande, Syed S Hissar, Shiv Kumar Sarin
BACKGROUND: Dendritic cells (DCs) promote pathogen recognition, uptake and presentation of antigen through DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) and toll-like receptors (TLRs). AIMS AND OBJECTIVES: We aimed to study temporal changes in DCs, TLRs and DC-SIGN during acute viral hepatitis B (AVHB) infection and compare them to chronic (CHB) and to investigate the earliest time point of activated pathogen recognition receptors in hepatitis B viral infection...
November 2016: Hepatology International
https://www.readbyqxmd.com/read/27649967/autoimmune-liver-diseases-in-the-asia-pacific-region-proceedings-of-apasl-symposium-on-aih-and-pbc-2016
#20
REVIEW
Atsushi Tanaka, Xiong Ma, Osamu Yokosuka, Martin Weltman, Hong You, Deepak N Amarapurkar, Yoon Jun Kim, Zaigham Abbas, Diana A Payawal, Ming-Ling Chang, Cumali Efe, Ersan Ozaslan, Masanori Abe, Robert Mitchell-Thain, Mikio Zeniya, Kwang Hyub Han, John M Vierling, Hajime Takikawa
During the 25th annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL 2016) in Tokyo, we organized and moderated an inaugural satellite symposium on the autoimmune liver diseases, autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). Following the keynote lecture by John M. Vierling (USA), speakers from the Asia-Pacific region provided an up-to-date perspective on the epidemiology, clinical practice and research in AIH and PBC in the Asia-Pacific region. Although epidemiology and clinical features of AIH seem to be similar in East Asia compared to those in western countries, the majority of patients with AIH are detected at an advanced stage and have higher mortality rates in South Asia, indicating an unmet need for earlier diagnosis and the initiation of appropriate immunosuppressive treatment...
November 2016: Hepatology International
journal
journal
41620
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"